ArticleCancer immunology, immunotherapy : CII2022

Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade.

Naoki Okada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.